Carfilzomib is a prescription drug introduced for the treatment of adult patients with relapsed/refractory MM who have received one to three previous treatments for multiple myeloma. The carfilzomib price in India may vary from around Rs. 9990 to Rs. 47325 for a supply of a vial of 1 injection.
The usual dose of carfilzomib is administered as an intravenous (IV) infusion. It is approved for use together with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, which are other existing agents used in the treatment of patients with multiple myeloma.